Format

Send to

Choose Destination
Trends Mol Med. 2014 May;20(5):251-60. doi: 10.1016/j.molmed.2014.01.004. Epub 2014 Jan 31.

Polycystin-1: a master regulator of intersecting cystic pathways.

Author information

1
Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA. Electronic address: sorin.fedeles@yale.edu.
2
Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
3
Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA; Department of Genetics, Yale University School of Medicine, New Haven, CT, USA. Electronic address: stefan.somlo@yale.edu.

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is the most common potentially lethal monogenic disorder, with more than 12 million cases worldwide. The two causative genes for ADPKD, PKD1 and PKD2, encode protein products polycystin-1 (PC1) and polycystin-2 (PC2 or TRPP2), respectively. Recent data have shed light on the role of PC1 in regulating the severity of the cystic phenotypes in ADPKD, autosomal recessive polycystic kidney disease (ARPKD), and isolated autosomal dominant polycystic liver disease (ADPLD). These studies showed that the rate for cyst growth was a regulated trait, a process that can be either sped up or slowed down by alterations in functional PC1. These findings redefine the previous understanding that cyst formation occurs as an 'on-off' process. Here, we review these and other related studies with an emphasis on their translational implications for polycystic diseases.

KEYWORDS:

chaperone therapy; cyst progression; polycystic kidney disease; polycystic liver disease; polycystin-1 dosage; protein biogenesis

PMID:
24491980
PMCID:
PMC4008641
DOI:
10.1016/j.molmed.2014.01.004
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center